Spesolimab Drug Asset Due Diligence Report 2026

This Spesolimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Spesolimab can convert its Monoclonal antibody profile and IL-36R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Spesolimab (query alias: spesolimab)
Modality / target	Monoclonal antibody; IL-36R; IL-36R inhibitors
Highest global status	Approved
Originator	Boehringer Ingelheim International GmbH
Active developers	Boehringer Ingelheim Pharmaceuticals, Inc., LEO Pharma A/S, Boehringer Ingelheim GmbH

The MCP disease footprint includes Pustular psoriasis, Generalized Pustular Psoriasis, Pyoderma Gangrenosum. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600121266	Phase 4	Not yet recruiting	25	The EASI 75 response rate at week 16
NCT06624670	Phase 3	Recruiting	90	Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later)
NCT06520514	Phase 1	Completed	60	Occurrence of any treatment-emergent adverse event

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)

Phase 2/3; n=39; evaluation: not stated. Reported fields: Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 3 Participants ; Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 5 Participants ; Occurrence of Treatment Emergent Adverse Events (TEAE) up to the End of Maintenance Treatment Period = 6 Participants

Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab

Phase 2; n=5; evaluation: not stated. Reported fields: Change in Global Pyoderma Gangrenosum (GPG) Severity Score(Mean) = -3 score on a scale (Standard Deviation, 2); -; -

Efficacy and Safety of IL-36 inhibitors in Generalized Pustular Psoriasis: A Systematic Review and Single-arm Meta-Analysis

Not Applicable; n=233; evaluation: Positive. Reported fields: GPPGA(0/1（week 12）) = 61.88 % ( 49.02 - 73.27); GPPGA(0/1（week 12）) = 77.78 % ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Spesolimab addresses Pustular psoriasis, Generalized Pustular Psoriasis, Pyoderma Gangrenosum. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-07-14	LEO Pharma closes deal for Spevigo®	Approved	US$105.1M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Use of Anti-il-36r antibodies for the treatment of hidradentitis suppurativa (HS)”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO